UK Court Revokes 2 Novartis Patents In Bone Drug Row

Law360, Los Angeles (March 15, 2013, 8:18 PM EDT) -- A U.K. court on Friday revoked two European patents for zoledronate, agreeing with generic-drug makers Hospira UK Ltd. and Mylan Inc. that Novartis AG wasn't the first to discover its effectiveness as an osteoporosis treatment.

The U.K. High Court of Justice sided with Hospira and Mylan over the idea that treating osteoporosis with zoledronic acid, also known as zoledronate, was common in the scientific community when Novartis filed its European patents for zoledronate in June 2000.

"It was generally considered that appropriate doses of suitable bisphosphonates...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.